Bing Yao, ArriVent Biopharma CEO

With one of biotech's largest pri­vate rounds in a year, Ar­riVent en­ters PhI­II

Bing Yao’s Ar­riVent Bio­phar­ma has amassed a $155 mil­lion over­sub­scribed Se­ries B, crown­ing it as one of biotech’s largest pri­vate rounds in a year-long dif­fi­cult …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.